HAP Trading’s VistaGen Therapeutics VTGN Stock Holding History

HAP Trading’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-11,053	Closed	-$292K	–	2103
2022 Q2	$292K	Buy	+11,053	New	+$390K	0.01%	581

Other funds holding VTGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

HAP Trading's VTGN Position: Q3 2022 in Review

HAP Trading sold out of VistaGen Therapeutics (VTGN) in Q3 2022, closing a stake of 11,053 shares — an estimated $292K sold.

HAP Trading first reported a position in VTGN in Q2 2022 and held it in 1 quarter. The position peaked at $292K in Q2 2022. 92 funds tracked by Wall St. Rank hold VTGN as of Q3 2022.

HAP Trading reported no remaining VistaGen Therapeutics position as of Q3 2022 after selling out during the quarter.
HAP Trading sold 11,053 VistaGen Therapeutics shares in Q3 2022, an estimated $292K.
HAP Trading first reported a position in VistaGen Therapeutics in Q2 2022 and held it in 1 quarter.
HAP Trading's VistaGen Therapeutics position peaked at $292K in Q2 2022.
92 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2022.

Based on HAP Trading's 13F filing for Q3 2022, filed 14 Nov 2022.